Navigation Links
Genencor Appoints New Executive Vice President - Technical Enzymes
Date:10/1/2007

Glenn E. Nedwin, Ph.D., MBA to Join Genencor's Senior Management Team

ROCHESTER, N.Y., Oct. 1 /PRNewswire/ -- Genencor, a division of Danisco A/S, today announced that Dr. Glenn E. Nedwin will join the Division as Executive Vice President - Technical Enzymes, effective Oct. 1, 2007. As a member of the Genencor Senior Management Team, Dr. Nedwin will head the division's activities in Grain Processing (which includes current fuel ethanol business), Textiles, Specialties & Market Development. He will report directly to Genencor's CEO Tjerk de Ruiter.

Dr. Nedwin comes to Genencor from being Interim President and Chief Science Officer at Dyadic International, Inc., a biotech company active in the bioenergy and industrial enzymes fields. Prior to joining Dyadic, Dr. Nedwin was President of Novozymes, Inc., where he established the company's US R&D headquarters for Novozymes A/S, as well being active in business development. In addition to his 14+ years with Novozymes, his career has included key positions with XOMA Corporation, Ideon Corporation, Molecular Therapeutics, Inc., and Genentech, Inc.

Dr. Nedwin's appointment continues to enhance Genencor's world-class, organization and Management Team. "He brings both established leadership and international business experience with him to the division," said Tjerk de Ruiter, CEO of Genencor. "Our goal is to be the growth engine of Industrial Biotechnology and Dr. Nedwin's experience and vision will certainly help us get there."

In addition to de Ruiter and Nedwin, the Genencor Senior Management Team includes James Laughton, Executive Vice President - Food & Feed; Philippe Lavielle, Executive Vice President - Business Development; Michael Arbige, PhD., Executive Vice President - Technology; Carole Cobb, Senior Vice President - Global Supply; Jim Sjoerdsma, Senior Vice President - Human Resources; and Andrew Ashworth, Vice President - Finance.

About Genencor

Genencor, a division of Danisco A/S, is a leader in the industrial biotechnology sector. In more than 40 countries, Genencor's 1,500 employees develop and market innovative enzymes and biobased solutions to improve the performance and reduce the environmental impact of a wide variety of industries, from laundry detergents to transportation fuels. Genencor also develops and produces enzymes for the food, beverage and animal nutrition industries, which are sold under the Danisco brand. In partnership with our customers, technology leaders and other stakeholders, Genencor's cutting-edge biotech platform provides competitive and sustainable solutions to the world, positioning Genencor as one of the leaders in the emerging biobased economy.


'/>"/>
SOURCE Genencor
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):